Scinovex
articleTop 1% cited

A Variable-dosing Regimen with Intravitreal Ranibizumab for Neovascular Age-related Macular Degeneration: Year 2 of the PrONTO Study

American Journal of Ophthalmology · 2009 · Vol. 148(1) · pp. 43–58.e1
Geeta A. LalwaniPhilip J. RosenfeldAnne E. FungSander R. DubovyS. MichelsWilliam J. FeuerJanet L. DavisHarry W. FlynnMaria Esquiabro
Retinal Diseases and TreatmentsRetinal and Optic ConditionsRetinal Imaging and AnalysisRanibizumabMedicineMacular degenerationOphthalmologyDosingVisual acuityRegimenProspective cohort studyChoroidal neovascularizationPro re nata

MeSH terms

RanibizumabAgedAged, 80 and overAntibodies, MonoclonalFemaleFluorescein AngiographyFollow-Up StudiesHumansInjectionsMacular DegenerationMaleMiddle AgedProspective StudiesVisual AcuityVitreous Body
Citation Network

How this paper connects to the literature. Drag to explore, click any node to open that paper.

A Variable-dosing Regimen with Intravitreal Ranibizumab for Neovascular Age-related Macular Degeneration: Year 2 of the PrONTO Study · Scinovex